The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) saw some unusual options trading on Tuesday. Investors bought 66,549 call options on the company. This represents an increase of approximately 37% ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the dual ...

President-elect Donald Trump, a Biden administration proposal would require Medicare and Medicaid to cover weight-loss drugs ...

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...